Precision Oncology combines specialized cancer research expertise with pioneering work in biomarkers to create a clinical research organization dedicated to the development of targeted agents in oncology. Our novel approach of combining clinical development and bioanalytics enhances the predictability of achieving study goals and obtaining objective data to inform future development decisions. Our efficient, oncology focused clinical operations, in combination with our up-front biomarker planning and execution, provide our sponsors with seamlessly integrated services to accelerate the pathway from first-in-man to proof-of-concept.
Precision Oncology Site Network
Precision Oncology’s site network offers sponsors a “turn-key menu” of qualified oncology sites with capabilities aligned to sponsors goals, including a commitment and track record of a 90-day study start-up.Read More
Adaptive Designs – Basket Trials and the Future
Adaptive designs are commonly applied to facilitate decision-making during a clinical trial and to lend early insight into anti-cancer activity. We routinely conduct combined dose escalation/dose expansion designs to quickly move from Phase I into Phase II for proof-of-concept. We refine patient selection by applying adaptive designs to evaluate a novel agent across multiple tumor types and combine biomarker and clinical data to drive decisions on the optimal tumor target(s) for further pursuit. By engaging sites from our Precision Oncology Site Network, as well as other reputable cancer centers with strong multi-disciplinary patient contributions, we are able to efficiently and predictably complete the targeted enrollment and effectively advance the progress toward approval.Read More
Infographic: An Accelerated Pathway for Oncology Development
Our fully integrated and novel approach to oncology drug development is fulfilling unmet needs in oncology drug development.Read More